Drug class
C1 Esterase Inhibitors (Acute)
C1 esterase inhibitors (acute) represent a functional therapeutic drug category consisting of intravenous human plasma-derived or recombinant C1 esterase inhibitor replacement therapies formulated for on-demand intervention. Read more about C1 Esterase Inhibitors (Acute)
3 drugs in this class 2 manufacturers
Drugs in C1 Esterase Inhibitors (Acute)
BERINERT (C1 esterase inhibitor)
BERINERT (C1 esterase inhibitor)
C1 esterase inhibitors (acute) represent a functional therapeutic drug category consisting of intravenous human plasma-derived or recombinant C1 esterase inhibitor replacement therapies formulated for on-demand intervention.
These agents function by replenishing deficient or dysfunctional endogenous C1 esterase inhibitor protein, thereby suppressing the classical complement pathway and the contact activation (kallikrein-kinin) cascade to halt excess bradykinin generation and reduce vascular permeability.
Clinically, this class is utilized for the rapid termination of acute abdominal, facial, peripheral, or life-threatening laryngeal swelling attacks in patients with hereditary angioedema.
-
medlineplus.gov
C1 esterase inhibitors (acute) represent a functional therapeutic drug category consisting of intravenous human plasma-derived or recombinant C1 esterase inhibitor replacement therapies formulated for on-demand intervention These agents function by replenishing deficient or dysfunctional endogenous C1 esterase inhibitor protein, thereby suppressing the classical complement pathway and the contact activation (kallikrein-kinin) cascade to halt excess bradykinin generation and reduce vascular perme...
-
nih.gov
C1 esterase inhibitors (acute) represent a functional therapeutic drug category consisting of intravenous human plasma-derived or recombinant C1 esterase inhibitor replacement therapies formulated for on-demand intervention
-
csl.com
These agents function by replenishing deficient or dysfunctional endogenous C1 esterase inhibitor protein, thereby suppressing the classical complement pathway and the contact activation (kallikrein-kinin) cascade to halt excess bradykinin generation and reduce vascular permeability
-
fda.gov
Clinically, this class is utilized for the rapid termination of acute abdominal, facial, peripheral, or life-threatening laryngeal swelling attacks in patients with hereditary angioedema
-
nih.gov
Clinically, this class is utilized for the rapid termination of acute abdominal, facial, peripheral, or life-threatening laryngeal swelling attacks in patients with hereditary angioedema
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.